Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse

The risk of central nervous system (CNS) dissemination in mantle cell lymphoma (MCL) is low and occurs late in the course of the disease. However, prognosis in such cases remains extremely poor despite high-dose antimetabolite chemotherapy. Among novel drugs used to treat relapsing MCL patients, ibr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Bernard, Sophie, Goldwirt, Lauriane, Amorim, Sandy, Brice, Pauline, Brière, Josette, de Kerviler, Eric, Mourah, Samia, Sauvageon, Hélène, Thieblemont, Catherine
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591793/
https://ncbi.nlm.nih.gov/pubmed/26239089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-647834
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados